Conclusions. There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
PMID: 21486104 [PubMed – in process] (Source: The World Journal of Biological Psychiatry)
Monthly Archives: March 2011
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence.
Conclusions. There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
PMID: 21486104 [PubMed – in process] (Source: The World Journal of Biological Psychiatry)
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence.
Conclusions. There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
PMID: 21486104 [PubMed – in process] (Source: The World Journal of Biological Psychiatry)
An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report
Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors report a case of probable non-lethal overdose during dose induction of a non-tolerant prisoner and discuss appropriate dosing under similar circumstances.
(C) 2011 Lippincott Williams & Wilkins, Inc. (Source: Addictive Disorders and Their Treatment)
MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report
Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors report a case of probable non-lethal overdose during dose induction of a non-tolerant prisoner and discuss appropriate dosing under similar circumstances.
(C) 2011 Lippincott Williams & Wilkins, Inc. (Source: Addictive Disorders and Their Treatment)
An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report
Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors report a case of probable non-lethal overdose during dose induction of a non-tolerant prisoner and discuss appropriate dosing under similar circumstances.
(C) 2011 Lippincott Williams & Wilkins, Inc. (Source: Addictive Disorders and Their Treatment)
Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone.
Conclusions and Scientific Significance: This study further elucidates the effects of TPV/r on glucuronidation. The current evaluation of glucuronide metabolites of BUP and norBUP are suggestive of combined inhibition of Uridine diphosphate (UDP)-glucuronosyltransferase of the 1A family and cytochrome P450 3A4 that spares UGT2B7 leading to a shunting of BUP away from production of norBUP and toward BUP-3G as seen by a statistically significant increase in the AUC of BUP-3G.
PMID: 21438849 [PubMed – as supplied by publisher] (Source: The American Journal of Drug and Alcohol Abuse)
Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone.
Conclusions and Scientific Significance: This study further elucidates the effects of TPV/r on glucuronidation. The current evaluation of glucuronide metabolites of BUP and norBUP are suggestive of combined inhibition of Uridine diphosphate (UDP)-glucuronosyltransferase of the 1A family and cytochrome P450 3A4 that spares UGT2B7 leading to a shunting of BUP away from production of norBUP and toward BUP-3G as seen by a statistically significant increase in the AUC of BUP-3G.
PMID: 21438849 [PubMed – as supplied by publisher] (Source: The American Journal of Drug and Alcohol Abuse)
Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone.
Conclusions and Scientific Significance: This study further elucidates the effects of TPV/r on glucuronidation. The current evaluation of glucuronide metabolites of BUP and norBUP are suggestive of combined inhibition of Uridine diphosphate (UDP)-glucuronosyltransferase of the 1A family and cytochrome P450 3A4 that spares UGT2B7 leading to a shunting of BUP away from production of norBUP and toward BUP-3G as seen by a statistically significant increase in the AUC of BUP-3G.
PMID: 21438849 [PubMed – as supplied by publisher] (Source: The American Journal of Drug and Alcohol Abuse)
Collaborative Care of Opioid-Addicted Patients in Primary Care Using Buprenorphine: Five-Year Experience [Original Investigation]
Conclusion Collaborative care with nurse care managers in an urban primary care practice is an alternative and successful treatment method for most patients with opioid addiction that makes effective use of time for physicians who prescribe buprenorphine. (Source: Archives of Internal Medicine)